Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Ramucirumab versus Docetaxel + Placebo in Stage IV NSCLC after Platinum Therapy
2010-021297-11Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ramucirumab + Docetaxel with Docetaxel + Placebo (2 arms). Primary endpoint: Overall survival. Started Oct 2010; status: completed.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-021297-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021297-11.